New imaging strategy after heart valve procedure shows promise in pilot study
NCT ID NCT02797158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a strategy to decide which patients need additional artery-opening treatment after a TAVI heart valve procedure. Researchers used a special imaging scan (SPECT) to look for areas of the heart not getting enough blood. The goal was to see if this imaging-guided approach could safely guide treatment decisions in 71 patients with severe aortic stenosis and stable coronary artery disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
71 people
The number who actually took part.
- Started
-
Jun 2016
- Finished
-
Jul 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients older than 18 years * Severe and symptomatic aortic stenosis defined as a median trans-valvular gradient higher than 40 mmHg and an aortic valve area of less than 1.0 cm2 or 0,6 cm2/m2 on echocardiography associated to significant CAD defined by ≥1 stenosis of ≥70% in a major epicardial coronary artery or ≥50% for left main * Patients is not candidate for surgical aortic valve replacement after the multidisciplinary heart team decision. Exclusion Criteria: * Recent acute coronary syndrome (within 30 days before randomization), * Unprotected left main disease * Critical stenosis (\>90%) of Left Anterior Descending artery (LAD), * Significant angina (CCS class more than 2) * Active bleeding, * Contraindication for tomographic technetium-99 assessment or dipyridamole injection * Previous enrollment in a other study * Impossibly to obtain consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe and symptomatic aortic stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montpellier University Hospital
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.